calcification

Etidronic acid (HEDP) is a diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.

Sodium etidronate (Didronel) is a synthetic therapeutic diphosphonate analog of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, Sodium etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis. This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption. Etidronate may also directly stimulate bone formation by osteoblasts.

Upacicalcet (AJT-240) is an intraventricular calcium mimetic, a SHPT available for human hemodialysis, that inhibits excessive parathyroid hormone (PTH) secretion by directly acting on parathyroid cell membrane calcium-sensitive receptors, thereby lowering blood levels of PTH.Upacicalcet is an orthosteric modulator of calcium-sensitive receptors and prevents adenine-induced secondary vascular calcification and bone disease in a rat model of adenine-induced secondary hyperparathyroidism.

Calindol hydrochloride is a potent orthosteric modulator (EC50: 132 nM) of the putative calcium-calcium-sensitive receptor (CaSR), inhibits Pi-induced VC, and delays the progression of calcification in vascular smooth muscle cells.

Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.

Clodronate disodium tetrahydrate (Clastoban) inhibits bone resorption and soft tissue calcification.

1-Methyl-2-undecyl-4(1H)-quinolone, along with dihydroevocarpine and evodiamine, should serve as chemical markers for the quality control of Evodia rutaecarpa (Juss.) Benth. This compound selectively inhibits type B MAO (MAO-B) activity with an IC(50) value of 15.3 microM using the substrate kynuramine, while not inhibiting type A MAO (MAO-A) activity. It can mitigate high phosphate-induced calcification in human aortic valve interstitial cells (HAVICs) by inhibiting phosphate cotransporter (PiT-1) gene expression and exhibits moderate antiangiogenic activity against human tumor cells.

Hexasodium phytate is used potentially to treat vascular calcification and calciphylaxis.

2,3-Diphospho-D-glyceric acid pentasodium salt is a highly anionic polyphosphorus compound located within the concave center of red blood cells, where it decreases oxygen affinity by binding to hemoglobin. This endogenous compound selectively inhibits vascular calcification (VC) and effectively postpones the formation of crystalline calpain particles (CPP). Additionally, it inhibits calcification in the mouse vascular smooth muscle cell line (MOVAS) without eliciting cytotoxic effects [1].

Osteocalcin (1-49) is a non-collagenous peptide that is secreted by osteoblasts and odontoblasts and comprises 1-2% of the total protein in bone. Secretion of osteocalcin (1-49) is stimulated by 1,25-dihydroxy vitamin D and plasma levels increase in diseases that induce dysregulated bone turnover such as osteoporosis, Paget's disease, and primary hyperparathyroidism. Osteocalcin (1-49) is positively correlated with insulin sensitivity and negatively correlated with high blood glucose levels in women. In vitro, osteocalcin induces chemotaxis of MDA-MB-231 breast cancer cells, human peripheral blood monocytes, and rat osteosarcoma cells with osteoblast-like characteristics. It is also expressed by vascular smooth muscle cells (VSMCs) displaying an osteoblast-like phenotype and has been positively associated with calcification of aortic tissue and heart valves in humans.